Regulation of PPARα by APP in Alzheimer disease affects the pharmacological modulation of synaptic activity.
Aged
Aged, 80 and over
Alzheimer Disease
/ drug therapy
Amyloid beta-Protein Precursor
/ genetics
Animals
Case-Control Studies
Cell Line
Cerebral Cortex
/ cytology
Disease Models, Animal
Female
Gene Duplication
Gene Expression Regulation
Humans
Lipogenesis
/ genetics
Male
Mice, Transgenic
Neurons
PPAR alpha
/ agonists
Synapses
/ drug effects
Alzheimer disease
Mouse models
Neuroscience
Journal
JCI insight
ISSN: 2379-3708
Titre abrégé: JCI Insight
Pays: United States
ID NLM: 101676073
Informations de publication
Date de publication:
23 08 2021
23 08 2021
Historique:
received:
30
03
2021
accepted:
30
06
2021
pubmed:
7
7
2021
medline:
26
2
2022
entrez:
6
7
2021
Statut:
epublish
Résumé
Among genetic susceptibility loci associated with late-onset Alzheimer disease (LOAD), genetic polymorphisms identified in genes encoding lipid carriers led to the hypothesis that a disruption of lipid metabolism could promote disease progression. We previously reported that amyloid precursor protein (APP) involved in Alzheimer disease (AD) physiopathology impairs lipid synthesis needed for cortical networks' activity and that activation of peroxisome proliferator-activated receptor α (PPARα), a metabolic regulator involved in lipid metabolism, improves synaptic plasticity in an AD mouse model. These observations led us to investigate a possible correlation between PPARα function and full-length APP expression. Here, we report that PPARα expression and activation were inversely related to APP expression both in LOAD brains and in early-onset AD cases with a duplication of the APP gene, but not in control human brains. Moreover, human APP expression decreased PPARA expression and its related target genes in transgenic mice and in cultured cortical cells, while opposite results were observed in APP-silenced cortical networks. In cultured neurons, APP-mediated decrease or increase in synaptic activity was corrected by a PPARα-specific agonist and antagonist, respectively. APP-mediated control of synaptic activity was abolished following PPARα deficiency, indicating a key function of PPARα in this process.
Identifiants
pubmed: 34228639
pii: e150099
doi: 10.1172/jci.insight.150099
pmc: PMC8410016
doi:
pii:
Substances chimiques
APP protein, human
0
Amyloid beta-Protein Precursor
0
PPAR alpha
0
PPARA protein, human
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
Front Cell Neurosci. 2015 Feb 02;8:469
pubmed: 25698923
J Pharm Biomed Anal. 2015 Jan;102:425-35
pubmed: 25459942
PLoS Med. 2017 Mar 21;14(3):e1002266
pubmed: 28323825
J Biol Chem. 2005 Dec 9;280(49):41057-68
pubmed: 16204253
Nat Genet. 2006 Jan;38(1):24-6
pubmed: 16369530
Cells. 2020 May 14;9(5):
pubmed: 32422896
Dement Geriatr Cogn Disord. 2004;18(3-4):245-9
pubmed: 15286454
Neurobiol Aging. 2009 Apr;30(4):666-8
pubmed: 17850927
J Neurosci. 2000 Jun 1;20(11):4050-8
pubmed: 10818140
Nat Rev Neurosci. 2011 May;12(5):284-96
pubmed: 21448224
Nature. 2002 Feb 14;415(6873):813-7
pubmed: 11845213
J Endocrinol. 2018 Jun;237(3):311-322
pubmed: 29674342
J Neurosci. 2014 Mar 12;34(11):3826-40
pubmed: 24623762
Science. 2002 Oct 25;298(5594):789-91
pubmed: 12399581
Proc Natl Acad Sci U S A. 2015 Jul 7;112(27):8445-50
pubmed: 26080426
J Alzheimers Dis. 2017;57(4):1171-1183
pubmed: 28304309
J Alzheimers Dis. 2009;18(4):935-52
pubmed: 19749434
Cell Rep. 2013 Aug 29;4(4):724-37
pubmed: 23972989
Eur J Neurol. 2018 Jan;25(1):59-70
pubmed: 28872215
EMBO Mol Med. 2016 Jun 01;8(6):595-608
pubmed: 27025652
Mol Neurodegener. 2020 May 29;15(1):30
pubmed: 32471464
Endocr Rev. 2018 Oct 1;39(5):760-802
pubmed: 30020428
Nature. 1993 Jan 7;361(6407):31-9
pubmed: 8421494
Exp Neurol. 1999 Oct;159(2):441-50
pubmed: 10506515
Elife. 2017 Jul 06;6:
pubmed: 28682239
Mol Neurodegener. 2013 Feb 02;8:8
pubmed: 23374228
Int J Mol Sci. 2020 Feb 22;21(4):
pubmed: 32098382
Neuroscientist. 2020 Jun;26(3):231-251
pubmed: 31779518
Can J Physiol Pharmacol. 1992;70 Suppl:S118-29
pubmed: 1295662
Neurochem Res. 2020 May;45(5):972-988
pubmed: 32170673
Front Neurosci. 2020 Jul 08;14:670
pubmed: 32733190
J Neurochem. 2017 Aug;142(3):407-419
pubmed: 28512781
Curr Neuropharmacol. 2012 Dec;10(4):393-403
pubmed: 23730261
Ann Neurol. 1983 Jan;13(1):72-8
pubmed: 6219611
Neurobiol Dis. 2019 Apr;124:379-395
pubmed: 30578827
Proc Natl Acad Sci U S A. 2007 Jan 2;104(1):353-8
pubmed: 17185415
J Neurosci. 2012 Jun 27;32(26):8940-51
pubmed: 22745494
Mol Cell Biol. 1995 Jun;15(6):3012-22
pubmed: 7539101
J Alzheimers Dis. 2015;48(4):1083-94
pubmed: 26402099
J Alzheimers Dis. 2012;28(3):561-6
pubmed: 22045488
Brain Dev. 2005 Jun;27(4):246-52
pubmed: 15862185
Sci Rep. 2017 Mar 23;7(1):370
pubmed: 28337033
Autophagy. 2020 Jan;16(1):52-69
pubmed: 30898012
Molecules. 2020 Jul 11;25(14):
pubmed: 32664475
Cancers (Basel). 2020 Nov 18;12(11):
pubmed: 33218188
EMBO Mol Med. 2013 Apr;5(4):608-25
pubmed: 23554170
J Neurosci. 2013 Apr 3;33(14):6203-11
pubmed: 23554501
Curr Opin Neurobiol. 2020 Apr;61:40-48
pubmed: 31863938
Brain. 2006 Nov;129(Pt 11):2966-76
pubmed: 16959815
J Neural Transm (Vienna). 2003 Sep;110(9):1041-50
pubmed: 12938026
Acta Neuropathol. 1989;77(6):569-75
pubmed: 2750476
Pediatr Neurol. 2017 Oct;75:101-102
pubmed: 28784285
Brain. 2006 Nov;129(Pt 11):2977-83
pubmed: 16921174
N Engl J Med. 2013 Jan 10;368(2):107-16
pubmed: 23150908
Life Sci Alliance. 2019 Mar 20;2(2):
pubmed: 30894406
Neuron. 2003 Mar 27;37(6):925-37
pubmed: 12670422
J Neurosci. 2006 Jul 5;26(27):7212-21
pubmed: 16822978
J Neural Transm (Vienna). 2005 Feb;112(2):239-53
pubmed: 15657641
Mol Neurodegener. 2020 Sep 14;15(1):53
pubmed: 32921309
Mol Aspects Med. 2011 Aug;32(4-6):247-57
pubmed: 22024249
Nat Rev Neurol. 2019 Mar;15(3):135-147
pubmed: 30733618
J Alzheimers Dis. 2006 Jul;9(2):167-81
pubmed: 16873964
Biochim Biophys Acta. 2013 Dec;1832(12):2368-78
pubmed: 24063855
EMBO J. 2017 Jun 1;36(11):1474-1492
pubmed: 28438892
Biochem Biophys Res Commun. 2008 Nov 21;376(3):478-82
pubmed: 18793612
Curr Alzheimer Res. 2009 Jun;6(3):238-51
pubmed: 19519305
Biochim Biophys Acta. 2016 May;1863(5):934-55
pubmed: 26686055
Biochim Biophys Acta. 2007 Aug;1771(8):1031-45
pubmed: 17569578
Neurobiol Dis. 2009 Mar;33(3):369-78
pubmed: 19101630
Neurobiol Aging. 2018 Jun;66:180.e1-180.e9
pubmed: 29503034
Biochem J. 2000 Mar 15;346 Pt 3:651-7
pubmed: 10698691
PPAR Res. 2010;2010:
pubmed: 20936127
Endocrinology. 2020 Feb 1;161(2):
pubmed: 31900483
Mol Neurodegener. 2019 Aug 2;14(1):32
pubmed: 31375134
J Cell Biol. 2018 Jul 2;217(7):2235-2246
pubmed: 29752396
Science. 2011 Jul 8;333(6039):233-8
pubmed: 21680814
Nutr Metab (Lond). 2014 Feb 12;11(1):10
pubmed: 24520982
Sci Rep. 2015 Dec 17;5:18286
pubmed: 26672557
Mol Metab. 2015 May 02;4(7):528-36
pubmed: 26137440
Sci Rep. 2017 Aug 29;7(1):9835
pubmed: 28852095
Hum Mol Genet. 2019 Nov 21;28(R2):R235-R240
pubmed: 31332445